The British manufacturer Astra Zeneca has issued a stark warning regarding the potential fallout from proposed budget cuts within the German healthcare system. Pascal Soriot, the CEO of the fifth-largest pharmaceutical conglomerate globally, informed the “Handelsblatt” that, starting next year, the company might cease bringing newly researched drugs to the German market.
Soriot insisted that this was not merely a threat, stating, “We are going to be attacked for this, but we have no other choice”. He justified the potential withdrawal from the German, and other European markets, by pointing to inescapable mathematics: “The financial impact on the business is simply too significant”. The core reasons cited for this financial distress are the planned savings measures in German statutory health insurance and persistent price pressure emanating from the United States.
The manager sharply critiqued the savings package proposed by the federal government for statutory health insurance. He warned that implementing these plans in Germany would restrict access to crucial innovations, jeopardize jobs, and increase systemic dependency on both China and the USA. Furthermore, Soriot cautioned that if German politics proceeds with the cost-cutting proposal, the United States would react negatively, which could subsequently affect any potential EU-US agreements concerning drug pricing.
Looking at a broader scope, Soriot predicted that Europe risks long-term loss of industrial importance and increased reliance on imports. He drew a parallel with other European sectors, stating that if nothing changes, Europe could lose this vital industry, just as it has already seen in technology and automotive.
According to Soriot, the government’s current plans for the statutory health insurance savings package have undermined the sector’s confidence in the viability of Germany as a base for major operations. He added that numerous pharmaceutical companies, which have made substantial investments in Germany in recent years, are deeply disappointed, having believed that Germany was moving in the right direction.
In the coming days, Soriot intends to hold further discussions at the Chancellery, joining his Swiss competitor, Roche’s CEO Thomas Schinecker, and other pharmaceutical executives.
